126 results about "Dry powder inhalation" patented technology

The invention provides a medication monitoring device and a medication monitoring method, relates to the field of medical apparatuses and instruments, and solves the technical problem that whether a capsule rotates to release medicines or not is difficult to monitor in a capsule type dry powder inhalation used in a transversely placed inhaler. The medication monitoring device comprises a shell and a photoelectric sensor, the photoelectric sensor is arranged on the shell, and a light path of the photoelectric sensor is configured to penetrate through the air inlet of the inhaler and the medicine bin, so that the rotation state of the capsule in the medicine bin is judged by detecting the change of the light path; the photoelectric sensor and the air inlet of the inhaler are arranged in a spaced mode in space so as to allow the inlet air flow to pass through. The rotation state of the capsule in the medicine bin is judged by detecting the change of the light path, whether the capsule rotates or not can be directly monitored, the problems that in the prior art, whether the capsule rotates or not cannot be known, and medicine taking failure caused by improper posture of the capsule cannot be judged are solved, effectiveness of medicine taking monitoring is ensured, and medicine taking guidance is facilitated.

A drug product includes a multidose dry powder inhalation device. The device has a medicament chamber and a desiccant chamber adjacent to the medicament chamber, and a pharmaceutical composition therein. The pharmaceutical composition includes a pharmaceutically acceptable salt of tanimilast. The desiccant chamber is filled with molecular sieves.

The invention discloses a budeagfor inhalation dry powder inhalation which comprises active ingredients, a carrier and a dispersing aid, and the active ingredients are budesonide, glycopyrronium bromide and formoterol fumarate dihydrate which are subjected to particle size grading. According to the invention, different drugs can be delivered to respective target sites of the lung through a particle size grading process of micronized active ingredients. The budigegfu inhalation dry powder inhalation is good in delivery dose uniformity and stable in delivery efficiency, and animal test results show that the product prepared by adopting the active component size grading method has obvious advantages in the aspects of safety and effectiveness.

The invention relates to an andrographolide nanocrystal suspension, preparation thereof and application of the andrographolide nanocrystal suspension in preparation of an andrographolide nanocrystal dry powder inhaler with an anti-inflammatory effect. The andrographolide nanocrystal suspension contains a) an active component andrographolide nanocrystal; b) a stabilizer; wherein the content of andrographolide in the suspension is 0.1%-30%, and the content of the stabilizer is 0.1%-5%. According to the andrographolide nanocrystal dry powder inhalant and the preparation method thereof, andrographolide nanocrystals are prepared into micro powder by adopting a spray drying technology, and auxiliary material addition and a preparation process are optimized, so that the andrographolide nanocrystal dry powder inhalant with good inhalation performance is successfully prepared and directly acts on the respiratory tract through a pulmonary drug delivery system, the administration dosage is reduced, and the inhalation effect is improved. Higher lung local concentration is obtained, the first-pass effect of the liver is avoided, meanwhile, the efflux effect of p-glycoprotein is avoided as much as possible, and then the bioavailability is improved; the technical problem that the bioavailability is poor due to the fact that andrographolide is excreted through p-glycoprotein and rapidly absorbed and metabolized in the intestinal tract is solved.

The present invention relates to (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), preferably in the form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (I) of formula (IMI) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2- The present invention relates to a pharmaceutical dry powder formulation comprising {[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (II) in combination with a lactose carrier comprising lactose monohydrate as a mixture of coarse and fine lactose, a process for producing such a pharmaceutical dry powder formulation, and its application for use in the treatment of cardiopulmonary disorders such as pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and pulmonary hypertension (PH) associated with chronic lung diseases (group 3 PH), such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP).

The invention relates to a nintedanib dry powder inhalant as well as a preparation method and application thereof. The dry powder inhalant comprises nintedanib and magnesium stearate. According to the nintedanib dry powder inhalant, by controlling the adding proportion of magnesium stearate and the particle size distribution of co-micro powder, the dosage of fine particles can be remarkably increased, the nintedanib dry powder inhalant still has the high dosage of fine particles under the high drug loading capacity, the drug bioavailability is high, and the safety risk of a patient in the medication period can be reduced. Meanwhile, the preparation method of the nintedanib dry powder inhalant is simple and controllable, and the final product is safe, reliable and high in stability.

A drug product includes a multidose dry powder inhalation device. The device has a medicament chamber and a desiccant chamber adjacent to the medicament chamber, and a pharmaceutical composition therein. The pharmaceutical composition includes a pharmaceutically acceptable salt of formoterol, optionally in combination with a pharmaceutically acceptable salt of glycopyrronium and / or beclomethasone dipropionate. The desiccant chamber is filled with molecular sieves.

The invention relates to the technical field of powder inhalation inhalers, in particular to a monitoring device for a capsule type powder inhalation inhaler. The monitoring device comprises a shell, the inhaler is installed on the shell, the shell is provided with a photoelectric sensor, the photoelectric sensor comprises an emitter and a receiver, the emitter and the receiver are arranged at the positions of two air inlets of the inhaler respectively, a set distance is reserved between the emitter and the air inlets, and a set distance is reserved between the receiver and the air inlets. The centers of the emitter, the receiver, the air inlet and the inhaler are positioned on the same straight line; the distance between the emitter and the air inlet and the distance between the receiver and the air inlet range from 0.99 mm to 8 mm. According to the invention, the airflow velocity can be indirectly obtained by directly monitoring the rotation state of the capsule, and meanwhile, the interference to normal air intake of the inhaler is reduced, so that the reliability and effectiveness of medication monitoring are improved.

The invention provides a posaconazole dry powder inhalant and a preparation method thereof, and relates to the technical field of medicine preparation. The posaconazole dry powder inhalant provided by the invention comprises posaconazole, a space stabilizer and a surfactant, has excellent aerodynamic performance, good redispersibility, higher solubility and dissolution rate and excellent antifungal activity, and in-vivo pharmacokinetic evaluation shows that the lung concentration is higher and the whole-body exposure is lower. The posaconazole dry powder inhalant is prepared by adopting a wet medium grinding and spray drying technology, and a nanocrystal technology is combined with pulmonary administration, so that the obtained posaconazole dry powder inhalant has excellent aerodynamic performance, good redispersibility, higher solubility and dissolution rate, and can be used for preparing a medicine for preventing and treating diseases. And a strategy with a wide prospect is provided for targeted delivery of a drug with poor solubility to an infected part deep in the lung.

The present invention relates to an ambroxol-ibuprofen cocrystal dry powder inhaler, a preparation method and application thereof, and belongs to the professional field of pharmaceutical preparations. The dry powder inhaler is mainly composed of ambroxol, ibuprofen and lactose, the molar ratio of ambroxol to ibuprofen is 1:1, and the mass ratio of lactose to ambroxol-ibuprofen cocrystal is 5-35%. The results of the rat lung tissue distribution experiment showed that the administration method of dry powder inhalation can significantly enhance the drug delivery efficiency in the lungs and greatly prolong the drug retention time in the lungs compared with the traditional intravenous administration. Pharmacodynamic experiments further revealed that the ambroxol-ibuprofen cocrystal dry powder inhaler can effectively inhibit the active expression of inflammatory factors in model animals, and reduce the accumulation of hydroxyproline (HYP) in lung tissue and serum, improve anti-fibrosis and anti-inflammatory capabilities, improve oxidative stress capabilities, thereby helping to delay the pathological process of pulmonary fibrosis, showing great development potential as an anti-pulmonary fibrosis drug.

The invention relates to an ambroxol and ibuprofen eutectic dry powder inhaler as well as a preparation method and application thereof, and belongs to the professional field of pharmaceutical preparations. The dry powder inhalant is mainly composed of ambroxol, ibuprofen and lactose, the molar ratio of ambroxol to ibuprofen is 1: 1, and the mass ratio of lactose to ambroxol and ibuprofen eutectic is 5-35%. A rat lung tissue distribution experiment result shows that compared with traditional intravenous administration, the delivery efficiency of the medicine in the lung can be remarkably enhanced by adopting a dry powder inhalation administration mode, and the retention time of the medicine in the lung is greatly prolonged. The pharmacodynamic experiment further reveals that the ambroxol and ibuprofen eutectic dry powder inhalant can effectively inhibit the active expression of inflammatory factors in a model animal body, reduce the accumulation of hydroxyproline (HYP) in lung tissues and serum, improve the anti-fibrosis and anti-inflammatory ability and improve the oxidative stress ability, so that the pathological process of pulmonary fibrosis is delayed, and the inhalant can be used for treating pulmonary fibrosis. The compound shows huge development potential as an anti-pulmonary fibrosis drug.

Disclosed is a dry-powder inhalable pharmaceutical composition, comprising an active ingredient and a first pharmaceutically acceptable excipient. The active ingredient comprises sildenafil or a pharmaceutically acceptable salt thereof. The first pharmaceutically acceptable excipient comprises an amino acid, a phospholipid, polylactic acid, a polylactic acid copolymer, a sugar alcohol, or a combination thereof. Some embodiments of the present invention further provide a method for preparing the dry-powder inhalable pharmaceutical composition. The dry-powder inhalable pharmaceutical composition can improve the aerosol properties, meet the requirements of inhalation administration, and further reduce the onset time.

The present invention relates to a method for preparing a dry powder inhalation formulation for preventing or treating idiopathic pulmonary fibrosis, the formulation being used in an inhalable-administration form through a dry powder inhaler, and the method comprising: step A of mixing polypeptides prepared as active pharmaceutical ingredients (APIs) and mannitol in distilled water; step B of freeze-drying the mixture mixed through step A; and step C of milling the mixture freeze-dried through step B at least once, thereby powderizing same, wherein the polypeptides prepared as active pharmaceutical ingredients comprise the amino acid sequence consisting of arginine (R, Arg)-glycine (G, Gly)-aspartic acid (D, Asp)-valine (V, Val)-phenylalanine (F, Phe)-proline (P, Pro)-serine (S, Ser)-tyrosine (Y, Tyr)-threonine (T, Thr)-lysine (K, Lys).

The present invention belongs to the technical field of medical devices, and particularly relates to a dry powder inhalation device with a rotating multi-capsule channel that is sequentially opened for inhalation, which is mainly used for administering in the form of a dry powder inhalant, and includes: a mouthpiece; a housing, a chamber is formed inside the housing; a plurality of capsule compartments are formed in the chamber and can be communicated with the mouthpiece; a diversion part is movably arranged between the mouthpiece and the plurality of capsule compartments to communicate the mouthpiece with one capsule compartment; a driving part is connected to the housing and the diversion assembly, and the driving part can rotate relative to the housing to drive the diversion assembly to move between the mouthpiece and the plurality of capsule compartments, so that different capsule compartments are communicated with the mouthpiece, solving the problem that: in the existing multi-capsule powder inhaler, when the user inhales the drug through the mouthpiece, the mouthpiece is communicated with each capsule compartment, resulting in the user's suction being dispersed into each capsule compartment, making it difficult for the user to inhale the drug, and thus reducing the inhalation efficiency.

The present invention relates to carrier particles for dry powder formulations for inhalation and a process for preparing the same.

The present invention relates to a pharmaceutical product comprising a single dose dry powder inhalation device and a pharmaceutical composition filled in a capsule, the pharmaceutical composition comprising micronized particles of a compound of formula (I) and a carrier. The invention also relates to a pharmaceutical or pharmaceutical composition for the treatment of respiratory diseases and to a method for the treatment of respiratory diseases. # imgabs0 #

A pharmaceutical composition for dry powder inhalation is provided, including an active ingredient and a pharmacologically acceptable excipient. The active ingredient includes an active compound with a molecular weight of less than 1000 Daltons. The pharmacologically acceptable excipient includes amino acid, sugar, sugar alcohol, polyol, phospholipid, or a combination thereof, or a combination thereof, in which a weight ratio of the pharmacologically acceptable excipient and the active ingredient is from 1:1 to 99:1. In some embodiments of the present disclosure, a method of preparing a pharmaceutical composition for dry powder inhalation is further provided. By regulating the amount of the pharmacologically acceptable excipient, the aerosol property of the pharmaceutical composition can be predominantly influenced by the pharmacologically acceptable excipient, thereby reducing the impact of the active ingredient on the aerosol property and expanding the range of the active ingredient applicable to the pharmaceutical composition.

A dry powder inhalation system includes a breath detection device, a drug delivery device, and a computing device. The breath detection device is configured to monitor the breathing state of an animal and transmit the signals of the breathing state. The drug delivery device is configured to deliver the dry powder orally or nasally to the lungs of the animal. The computing device is configured to receive the signals of the breathing state, evaluate a stress state of the animal, predict a breathing cycle of the animal, and control the drug delivery device to release the dry powder during a non-stressed inhalation period for the animal to inhale the dry powder autonomously. A dry powder administration method is also disclosed.

The invention discloses an application of a synephrine dry powder inhalant in preparation of a medicine for treating acute lung injury. According to the invention, the synephrine is prepared into a dry powder inhaler (DPI) dosage form, so that the problem of low bioavailability of the synephrine is overcome, and the synephrine is directly and actively targeted to the lung after being administered to the lung, so that the plasma concentration of the lung is increased, and the distribution of the medicine in other tissues is reduced, thereby improving the curative effect of the medicine and reducing the side effects of the whole body. Meanwhile, the first-pass effect is avoided by a dry powder inhalation mode, so that the stability of the medicine is facilitated, and the treatment compliance of a patient is improved by a non-invasive administration way. The invention provides a new thought for the research of a pulmonary drug delivery system, and has a wide clinical application prospect.

This invention relates to the field of filling equipment technology and discloses a storage-type automated filling equipment for dry powder inhalers. The equipment includes a workbench, a frame fixedly mounted on the top of the workbench, a mounting frame mounted on the top of the frame, a support frame fixedly mounted on the top of the mounting frame, and a drive motor mounted on the top of the support frame. The output shaft of the drive motor passes through the interior of the mounting frame and is fitted with a track. A rotating rod is rotatably mounted inside the mounting frame, and the bottom of the rotating rod passes through the interior of the mounting frame and is fixedly fitted with a rotating wheel. In this invention, a camera, a rotating wheel, a positioning wheel, a drive motor, and an electric push rod work together. The electric push rod pushes the positioning wheel to clamp the filling bottle, the drive motor drives the rotating wheel to rotate and adjust the bottle angle, and the camera identifies and positions the bottle in real time, accurately correcting the bottle placement to ensure precise alignment between the filling nozzle and the discharge port of the filling component.

The invention relates to the technical field of nasal preparation administration devices, in particular to a nasal dry powder inhalation administration device for children, which comprises a shell, an extrusion sealing mechanism, an auxiliary administration mechanism and a dose dividing mechanism. Wherein the dose dividing mechanism can realize accurate dose dividing and quantitative control of medicine powder according to physiological characteristics and medication requirements of children of different age groups; the auxiliary drug delivery mechanism is connected to the drug outlet end of the drug delivery pipe, the drug delivery path can be optimized according to the structural characteristics of the nasal cavity of a child, drugs are effectively guided to be deposited in the absorption area of the nasal cavity, and waste of the drugs in non-absorption areas such as the nasal vestibule is reduced; the extrusion sealing mechanism can stably spray out medicine powder in the shell through the medicine feeding pipe, and the medicine powder cooperates with the auxiliary medicine feeding mechanism, so that the delivery efficiency of the medicine in the nasal cavity is improved.

The present invention relates to pharmaceutical dry powder formulations, comprising (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), preferably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid monohydrate (II) of formula (I-M-II) in combination with a lactose carrier, comprising lactose monohydrate as a mixture of coarse lactose and fine lactose, and to the process of manufacturing such pharmaceutical dry powder formulations and its application for use in the treatment of cardiopulmonary disorders, such as pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP).

A dry powder inhalation formulation includes at least one active pharmaceutical ingredient (API) and a lipid matrix having at least one triglyceride chosen in the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and their mixture and its manufacturing method.

The present invention relates to a drug product comprising a single-dose dry powder inhalation device and a pharmaceutical composition loaded in a capsule, the pharmaceutical composition comprising micronized particles of the compound of formula (I) and a carrier. The present invention also relates to a pharmaceutical composition for use for the treatment of a respiratory disease and to a method for the treatment of a respiratory disease.

The present invention discloses a dry powder inhalation device, the device includes a container for powdered medicine, the device also includes a positioner for limiting an opening position of the container, and a driving structure for opening the container at the opening position, the device is formed with an outlet connected to the opened container, through which a user can inhale powdered medicine from the opened container, the positioner is provided with an airflow restriction member located between the positioner and the outlet, the airflow restriction member is connected to the positioner and the outlet, and the airflow resistance of the dry powder inhalation device is increased. The dry powder inhalation device with an additional airflow restriction member can meet the needs of delivering different medicines and achieve a good delivery effect.

The invention discloses a carrier-free mometasone furoate dry powder inhaler and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the carrier-free mometasone furoate dry powder inhaler comprises mometasone furoate and an excipient, and the preparation method comprises the following steps: firstly, mixing mometasone furoate and the excipient according to a mass ratio of 10: 90-90: 10, transferring into a beaker, adding a proper amount of water, stirring, and carrying out suction filtration; adding an ethanol-water mixed solution, and stirring until solids are completely dissolved to obtain a spray-dried raw material solution; carrying out spray drying on the spray drying raw material solution by adopting a spray dryer, and collecting a product after drying to obtain microspheres, namely the carrier-free mometasone furoate dry powder inhalant. According to the carrier-free mometasone furoate dry powder inhalant, lactose does not need to be used as a carrier, the allergy risk possibly caused by lactose is avoided, meanwhile, a microsphere structure with the surface wrinkled is formed through a spray drying technology, the medicine mainly exists in an amorphous state, and the dispersity and solubility of mometasone furoate are remarkably improved.

The present invention relates to a dry powder composition for an inhalation formulation comprising formoterol or a pharmaceutically acceptable salt thereof, a tiotropium bromide anhydride and a pharmaceutically acceptable carrier. The synthesis methods of the formoterol and the tiotropium bromide are respectively realized through specific chemical reaction steps, and finally high-purity active ingredients are obtained. The weight ratio of the active ingredients to the carrier in the composition is 1: (1-15): (50-50000), and the carrier can be selected from lactose, cane sugar, mannitol or amino acid and the like. The preparation method comprises the following steps: micronizing, mixing, filling into hollow capsules, and finally preparing a finished product through aluminum-plastic packaging. The composition disclosed by the invention has good chemical stability and high inhalation efficiency, can be kept for more than two years at normal temperature, and is accurately and uniformly administered in a targeted lung through a dry powder inhalation device, so that formoterol and tiotropium bromide synergistically play a role in relaxing bronchial smooth muscles, and clinical requirements are met.

To provide a system for delivering clofazimine to the lungs of a patient.SOLUTION: A system for use in providing antibiotic activity is provided including a dry powder inhalation device and a pharmaceutical composition. The pharmaceutical composition comprises clofazimine, or a pharmaceutically acceptable salt or derivative thereof, of one or more appropriate particle size, and a physiologically acceptable pharmacologically inert excipient, or a mixture of physiologically acceptable pharmacologically inert excipients of appropriate particle size or sizes. The clofazimine is provided in the form of finely divided particles having an aerodynamic mass median diameter of less than 5 μm.SELECTED DRAWING: None

A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

The invention relates to a polymyxin B sulfate dry powder inhalation and application thereof, which can effectively solve the problem of medication for treating pneumonia and pulmonary infection caused by multi-drug-resistant gram-negative bacteria, the polymyxin B sulfate dry powder inhalation is prepared from polymyxin B sulfate, leucine and mannitol, and the preparation method comprises the following steps: dissolving polymyxin B sulfate, leucine and mannitol in ultrapure water according to a mass ratio, carrying out ultrasonic treatment to obtain a uniformly mixed medicine solution, and carrying out freeze drying to obtain the polymyxin B sulfate dry powder inhalation. The composition is simple, scientific and reasonable, the raw materials are rich, the preparation method is easy to operate, the product quality is good, the composition is administrated through aerosol inhalation, the composition is effectively used for treating pneumonia and pulmonary infection caused by multi-drug-resistant gram-negative bacteria, the composition is fast to absorb, the pulmonary drug concentration is high, the stability is good, and the composition is suitable for clinical application. The medicine is a great innovation in treatment of pneumonia and pulmonary infection caused by the multi-drug-resistant gram-negative bacteria, and has remarkable economic and social benefits.